Zacks Investment Research upgraded shares of Curis, Inc. (NASDAQ:CRIS) from a sell rating to a hold rating in a report published on Monday.
According to Zacks, “Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis’ product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease. “
Several other brokerages have also recently commented on CRIS. ValuEngine raised Curis from a sell rating to a hold rating in a research report on Friday, September 1st. BidaskClub cut Curis from a hold rating to a sell rating in a research report on Thursday, July 27th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the stock. Curis currently has an average rating of Hold and an average target price of $6.00.
Curis (NASDAQ CRIS) traded down 0.8599% during midday trading on Monday, reaching $1.5565. The company had a trading volume of 245,394 shares. The company’s market cap is $223.95 million. The company’s 50-day moving average is $1.74 and its 200 day moving average is $1.93. Curis has a 52-week low of $1.47 and a 52-week high of $3.72.
Curis (NASDAQ:CRIS) last issued its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.01). Curis had a negative net margin of 836.18% and a negative return on equity of 236.43%. The company had revenue of $2.10 million for the quarter, compared to analyst estimates of $2.08 million. During the same period last year, the company posted ($0.09) earnings per share. The business’s revenue for the quarter was up 23.5% on a year-over-year basis. On average, equities research analysts forecast that Curis will post ($0.40) EPS for the current year.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. boosted its position in Curis by 1.6% during the second quarter. Goldman Sachs Group Inc. now owns 119,638 shares of the biotechnology company’s stock valued at $226,000 after purchasing an additional 1,880 shares during the last quarter. Rhumbline Advisers boosted its position in Curis by 1.9% during the second quarter. Rhumbline Advisers now owns 127,529 shares of the biotechnology company’s stock valued at $241,000 after purchasing an additional 2,340 shares during the last quarter. American International Group Inc. boosted its position in Curis by 7.1% during the first quarter. American International Group Inc. now owns 68,733 shares of the biotechnology company’s stock valued at $191,000 after purchasing an additional 4,560 shares during the last quarter. Weiss Multi Strategy Advisers LLC boosted its position in Curis by 4.8% during the first quarter. Weiss Multi Strategy Advisers LLC now owns 130,000 shares of the biotechnology company’s stock valued at $361,000 after purchasing an additional 6,000 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY boosted its position in Curis by 9.3% during the first quarter. Metropolitan Life Insurance Co. NY now owns 90,156 shares of the biotechnology company’s stock valued at $251,000 after purchasing an additional 7,638 shares during the last quarter. 44.72% of the stock is owned by hedge funds and other institutional investors.
Curis Company Profile
Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with our FREE daily email newsletter.